{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:23:09Z","timestamp":1794579789420,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diagmicrobio.2025.116994","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:01:11Z","timestamp":1751713271000},"page":"116994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6776-6467","authenticated-orcid":false,"given":"Mohammad","family":"Al Diab Al Azzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wejdan","family":"Abdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina","family":"Alhamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad Salman A.","family":"Alhothali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan Shukr","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind Mohammed","family":"Almajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan Ibrahim S.","family":"Alhamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah Nasser A.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla Osman","family":"Eltayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116994_bib0001","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciae363","article-title":"Treatment outcomes among patients with a positive Candida culture close to randomization receiving Rezafungin or Caspofungin in the ReSTORE study","volume":"79","author":"Soriano","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116994_bib0002","first-page":"5","article-title":"Candida species as potential nosocomial pathogens-A review","volume":"15","author":"Jahagirdar","year":"2018","journal-title":"Electron J Gen Med"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116994_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106229","article-title":"Attributable mortality of candidemia \u2013 Results from the ECMM Candida III multinational European Observational Cohort Study","volume":"89","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0004","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/CCM.0b013e31819efac0","article-title":"Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006)","volume":"37","author":"Leroy","year":"2009","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00134-008-1338-7","article-title":"Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis","volume":"35","author":"Guery","year":"2009","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2025.116994_bib0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10096-006-0159-2","article-title":"Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies","volume":"25","author":"Falagas","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.116994_bib0007","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0008","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116994_bib0009","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.4.5.807","article-title":"Caspofungin: first approved agent in a new class of antifungals","volume":"4","author":"Johnson","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: a novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116994_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of Rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0013","first-page":"e00646","article-title":"New perspectives on antimicrobial agents: rezafungin","volume":"69","author":"Forrister","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116994_bib0014","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.diagmicrobio.2025.116994_bib0016","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias. Accessed March 18, 2025. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0017","doi-asserted-by":"crossref","first-page":"e01584","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116994_bib0018","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciae363","article-title":"Treatment outcomes among patients with a positive Candida culture close to randomization receiving Rezafungin or Caspofungin in the ReSTORE study","volume":"79","author":"Soriano","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116994_bib0019","doi-asserted-by":"crossref","first-page":"E3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus Caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"10.1016\/j.diagmicrobio.2025.116994_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116994_bib0021","doi-asserted-by":"crossref","first-page":"E3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus Caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116994_bib0022","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciae363","article-title":"Treatment outcomes among patients with a positive Candida culture close to randomization receiving Rezafungin or Caspofungin in the ReSTORE study","volume":"79","author":"Soriano","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"10.1016\/j.diagmicrobio.2025.116994_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116994_bib0025","doi-asserted-by":"crossref","first-page":"E3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus Caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"10.1016\/j.diagmicrobio.2025.116994_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0027","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.007","article-title":"Invasive candidiasis in non-hematological patients","volume":"3","author":"Mikulska","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116994_bib0028","author":"Vincent"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116994_bib0029","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s12325-019-01115-0","article-title":"Choosing the right antifungal agent in ICU patients","volume":"36","author":"Chatelon","year":"2019","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116994_bib0030","first-page":"868","article-title":"Caspofungin","volume":"45","author":"Fotsing","year":"2024","journal-title":"Tagliche Praxis"},{"key":"10.1016\/j.diagmicrobio.2025.116994_bib0031","first-page":"1","article-title":"It\u2019s here, It\u2019s there, there\u2019s fungi everywhere: a case series utilizing rezafungin for invasive candidiasis","author":"Keck","year":"2025","journal-title":"Infectious Diseases and Therapy"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116994_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55729\/2000-9666.1391","article-title":"Game changer or more of the same? A comparative meta-analysis of Rezafungin and Caspofungin in treating candidemia and invasive candidiasis","volume":"14","author":"Sarfraz","year":"2024","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116994_bib0033","doi-asserted-by":"crossref","first-page":"106614","DOI":"10.1016\/j.ijantimicag.2022.106614","article-title":"Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses","volume":"60","author":"Domingos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"10370","key":"10.1016\/j.diagmicrobio.2025.116994_bib0034","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116994_bib0035","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus Caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116994_bib0036","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Honor\u00e9","year":"2024","journal-title":"Crit Care"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:38:32Z","timestamp":1755553112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325003177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0732889325003177"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116994","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116994"}}